Webinar Wednesdays, with PKD Foundation Chief Scientific Officer (CSO) David Baron, Ph.D., occur the third Wednesday of each month at Noon Central Time. These chats highlight targeted topics pertaining to the science of PKD.
Browse by Format
Guest speaker Peter Harris, Ph.D., from Mayo Clinic discusses what we know about PKD genes and how this information could be used to inform disease progression and develop potential treatments. Originally aired April 2017
Dr. Baron discusses regenerative medicine, including biomechanical kidneys and the next generation of renal treatments that could one day make dialysis and transplants a thing of the past.
A conversation with Timothy Kline, Ph.D.
PKD researcher Timothy Kline, Ph.D., discusses his PKD Foundation-funded project, which is focused on engaging technology to assess a PKD patient's prognosis and to judge the effectiveness of potential treatments.
Tyrosine kinase inhibitors & PKD
Learn about tyrosine kinase inhibitors (TKI) and their role as a potential treatment for polycystic kidney disease (PKD).
A closer look at clinical studies
Our Chief Scientific Officer talks about the clinical study process including how clinical studies are designed and how enrollment decisions are made. Originally aired: July 2016
Conversation with a researcher
Bradley Yoder, Ph.D., discusses the results of his recently completed PKD Foundation-funded project "In vivo analysis of cilia mechanosensation in the kidney."
Total Kidney Volume (TKV) and PKD
Total Kidney Volume (TKV) is a key biomarker for PKD clinical studies. Learn exactly what it means, how it is calculated and why it is an important tool for the development of new therapies for the treatment of PKD.
New gene editing technology: What it could mean for the future of PKD
Discover how a new gene-editing technology called 'CRISPR' could transform the future of PKD care.
PKD therapies and potential candidates
PKD Foundation Chief Scientific Officer David Baron, Ph.D. talks with guest speakers Alan Yu, M.D. and Ron Perrone, M.D. to discuss the latest in potential PKD therapies that are currently (or soon to be) in trial.
The sequence of drug development
Hear from PKD Foundation Chief Scientific Officer David Baron, Ph.D. as he uses his decades of experience in drug development to explain the process as it relates to PKD.